Spark Gets FDA Greenlight for Luxturna, The First Gene Therapy for Eye Disease Approved in the U.S. Post author:Sam Post published:December 18, 2017 Post category:BioPharma The FDA broke new ground today with a first-of-its-kind therapy for eye disease. Source: BioSpace You Might Also Like Why This Tiny SoCal Biopharma Could be a Real Threat to Mylan May 29, 2017 Dentsply Sirona Chairman, CEO and COO Resign in Management Shakeup October 3, 2017 Presbia Announces Extension Of Rights Offering February 22, 2017
